Table 3.

Treatment characteristics.

	Patients (N = 194)
Medication at onset of TKI discontinuation, n (%)
Imatinib	83 (42.8)
Nilotinib	69 (35.6)
Dasatinib	36 (18.6)
Bosutinib	2 (1.0)
Ponatinib	4 (2.0)
Dosage of imatinib before treatment cessation, n (%)
300 mg/d	52 (62.6)
200 mg/d	31 (37.4)
Dosage of nilotinib before treatment cessation, n (%)
200 mg/d	6 (8.7)
300 mg/d	21 (30.5)
400 mg/d	19 (27.5)
450 mg/d	12 (17.4)
600 mg/d	11 (15.9)
Dosage of dasatinib before treatment cessation, n (%)
20 mg/d	4 (11.1)
50 mg/d	20 (55.6)
80 mg/d	12 (33.3)
Dosage of bosutinib before treatment cessation, n (%)
400 mg/d	2 (100)
Dosage of ponatinib before treatment cessation, n (%)
15 mg/d	3 (75.0)
15 mg every other day	1 (25.0)